Vivo Opportunity, LLC - Oct 2, 2023 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role: 10%+ Owner
Signature: VIVO OPPORTUNITY, LLC, By: /s/ Hongbo Lu
Stock symbol: SLNO
Transactions as of: Oct 2, 2023
Transactions value $: $13,037,500
Form type: 4
Date filed: 10/4/2023, 04:30 PM
Previous filing: Sep 28, 2023
Next filing: Apr 3, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SLNO	Common Stock	Exercise of in-the-money or at-the-money derivative security	$13M	+5.22M	+162.81%	$2.50	8.42M	Oct 2, 2023	By Vivo Opportunity Fund Holdings, L.P.	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLNO	Tranche B Warrants (right to buy)	Exercise of in-the-money or at-the-money derivative security	$0	-5.22M	-100%	$0.00^*	0	Oct 2, 2023	Common Stock	5.22M	$2.50	By Vivo Opportunity Fund Holdings, L.P.	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2	The Tranche B Warrants are immediately exercisable and expire upon the earlier of (i) November 8, 2026 or (ii) 30 days following receipt of Food and Drug Administration's marketing approval of Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS).

Content

Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

The Tranche B Warrants are immediately exercisable and expire upon the earlier of (i) November 8, 2026 or (ii) 30 days following receipt of Food and Drug Administration's marketing approval of Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS).